Interest in adult growth hormone replacement has increased since identification of the associated vascular morbidity and mortality. Although total cholesterol and low density lipoprotein reduction and high density lipoprotein increases are anticipated, reports are conflicting and there is no uniformity in lipoprotein(a) changes. In 1990 we commenced an open trial of therapy with human recombinant GH and now have results to 36 months for 21 patients. Deficiency status was confirmed by insulin stress test with flat GH response < 2.0 ng/ml, mean insulin-like growth factor-I value 122 ng/ml (+/- 69 SD). Lipoprotein(a) was measured by monoclonal assay. Lipid analysis yields two subgroups: baseline cholesterol levels of greater or less than 6.22 mmol/l, with hypercholesterolaemic patients showing an enhanced hypolipaemic response. ANOVA was utilized, with 95% confidence limits. The most significant changes are of reductions in cholesterol and low density lipoprotein; the rate of change is greatest at 6 and 12 months but not sustained to 36 months. High density lipoprotein rises as expected, not to full significance. Lipoprotein(a) levels rose significantly in six patients of the cohort, and the increase was sustained over 36 months.

ABSTRACT Using a standard infusion of 500 mg of calcium gluconate, and collecting urine in four hourly fractions for 36 hours in patients whose calcium and phosphorus intake had been previously stabilised for 3 days a satisfactory difference in the degree of inhibition of phosphate excretion between cuparathyroidism, and hypo- and hyperparathyroidism was achieved. The value of the renal phosphorus threshold estimation is diminished by the finding of threshold figures between 2.0 and 3.0 mg/100 ml in both hyperparathyroidism and normal subjects.